A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Plasmodium Falciparum Malaria
Interventions
BIOLOGICAL

RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)

BIOLOGICAL

RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)

BIOLOGICAL

ChAd63 ME-TRAP (5 x 10^10 vp)

BIOLOGICAL

MVA ME-TRAP (2 x 10^8 pfu)

Trial Locations (4)

SO16 6YD

NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Oxford

GU2 7XP

Surrey Clinical Research Centre, University of Surrey, Guildford

W12 0HS

NIHR/Wellcome Trust Imperial CRF, Hammersmith Hospital, Imperial College NHS Trust, London

All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

collaborator

National Institute for Health Research, United Kingdom

OTHER_GOV

lead

University of Oxford

OTHER

NCT02252640 - A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S | Biotech Hunter | Biotech Hunter